TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Surgical site complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Surface Motion Camera (SMC) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p50 changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength MMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke (All, Serious, Non-Serious)
Endpoint domain: Adverse events/effects
Primary endpoint: New onset renal failure (within 30 days of index procedure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detection of microbial colonization or infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hematological causes of menorrhagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Consumption of nonopioid and weak opioid analgesics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent change of non-HDL-C from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TB disease prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incipient TB prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of active TB cases resulting from recent transmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of aerosolized Mtb in exhaled breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of children with CADVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change of visual analogue scale (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Event (safety)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in soft tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in tumor microenvironment subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Covid-19 active infection in households
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Covid-19 active infection in healthcare facilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of PrEP prescriptions written for each patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: LV remodeling index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Itching grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom score after operation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recovery of Urinary Continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Beck Anxiety Inventory II (BAI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Adverse Events/Serious Adverse Events Reported
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Fractional Synthesis Rate of Skeletal Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: RANKL/OPG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Firmness of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Presence of calcific deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of recalled International Index of Erectile Function-5
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent change from baseline (pre-ibutilide) in maximum QT-F and QT-Fram intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mother-Child Emotional Availability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mother-Child Interpersonal Synchrony
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of Participants with Abnormalities in Laboratory Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titer (GMT) of Mucosal Immunogenicity S-IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean fold rise (GMFR) of Mucosal Immunogenicity S-IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity Serum IgG: proportion of subjects with antibody concentration ≥0.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Growth rate at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional Intensity Morphing Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional Recognition Task-Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Face Affective Go No-Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adapted Cambridge Gambling Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reinforcement Learning Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discounting Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predicted Effect-site Concentration of Propofol (Ceprop)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertigo symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child-Parent Relationship Scale - Short Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Efficacy for Parenting Tasks Index - Toddler Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 400m Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of ataxia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Model discrimination (c-statistic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Model calibration (intercept)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Model calibration (slope)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maturation stages measured by CVMI index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in resting state Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Numeric pain rating scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Innate immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient satisfaction at first week
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction at first month
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative pain at 6th hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain at 24th hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fertility Awareness Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fertility Health Information Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of out-patients re-presenting to the ED
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-surgical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of radiation-associated acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Gamma camera-based whole-body [123I] I-(HE)3-G3 uptake value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPECT-based [99mTc]Tc-G3-(G3S)3C uptake value in tumor lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first hospitalization or death from all causes
Endpoint domain: Mortality/survival
Primary endpoint: Area under concentration-time curve from time 0 to infinity (AUCinf) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma (peak) drug concentration (Cmax) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under concentration-time curve from time 0 to infinity (AUCinf) of camizestrant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma (peak) drug concentration (Cmax) of camizestrant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulty of encounter as rated by trainee
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difficulty of encounter as rated by attending physician
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Delay or lack of acquisition of oral exploration of objects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of cycle 1 dose limiting toxicities of tiragolumab as monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of objective response for the combination of tiragolumab and atezolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of cycle 1 dose limiting toxicities of the combination of tiragolumab and atezolizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Symptoms 6 months after procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safe dose of PRG-2302 infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of AE after PRG-2302 infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Change of motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Self-Management Events
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of participants with Treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Serious Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Fk506 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep spindle during N2 sleep stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Sleep spindle during N3 sleep stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Stroke Specific Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Psychological impact of hospitalization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical impact of hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on procedural knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Impact on local care utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fugl Meyer Assessment Scale - Lower Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wisconsin Gait Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurements of volatile organic compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COSI Goal Achievement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: AQoL-8D Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Amino acid plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Mean Sitting Systolic Blood Pressure (MSSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Vaginal Delivery
Endpoint domain: Mortality/survival
Primary endpoint: Quality of intraoperative monitoring of the recurrent laryngeal nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite performance measures for CAD care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fluid intake compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in frequency of incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 16-week progression-free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Composite of death or mechanical ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Mini Balance Evaluation Systems Test (mini-BESTest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the intestinal microbiome community
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bilateral sentinel lymph node detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Responsiveness (change of mBI scores from admission to discharge)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of annoying sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-related adverse events (SDAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of T cell administration
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of T cell administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety record post IMP exposure
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change In Proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent change in Draining fistula/tunnel (dT) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bush Francis catatonia rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived usefulness/utility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Likelihood of using the skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time elapsed from EEG start to sleep stages with melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time elapsed from EEG start to sleep stages with deprivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Reporting Any Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Dynamization Interlocking Intramedullary Tibial Nail
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: liver complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Participants Alive and Respiratory Failure Free
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of IVDA among IE patients
Endpoint domain: Mortality/survival
Primary endpoint: Complications of IVDA among IE patients
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically Significant Disease (CSD) diagnosed post-baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at palpation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at stretch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-treatment sustained virologic response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Six Minutes Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pharmacodynamic normalized enrichment score (NES) from endobronchial biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in pharmacodynamic normalized enrichment score (NES) from bronchial brushings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in pharmacodynamic normalized enrichment score (NES) from nasal brushings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 2-week response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Skin Graft Take
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of Complete Remission or Complete Remission with Partial Hematologic Recovery (CR/CRh)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematologic outcomes
Primary endpoint: Change in Positive Affect Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Aspartate Aminotransferase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Sepsis development
Endpoint domain: Adverse events/effects
Primary endpoint: 6-month Progression-Free Survival (PFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC From Time Zero to Infinity (AUCinf) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial oxygen tension, PaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: P/F ratio or Horowitz index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients who are event-free
Endpoint domain: Mortality/survival
Primary endpoint: Glass ionomer sealant survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Nucleic acid negative rate in 5 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Virus CT value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time from randomization to first independently centrally adjudicated relapse (TTFR)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of investigational medicinal product (IMP)
Endpoint domain: Adverse events/effects
Primary endpoint: International Knee Documentation Committee score (IKDC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of Torque Development - Limb Symmetry Index (RFD-LSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with early allograft dysfunction (EAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical success at time of procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 6-month biological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate to severe pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate to severe pain with movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average postoperative narcotic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-Minute Walk Test (2MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up and GO (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 seconds sit to stand test (30SSTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in fasting serum triglyceride (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Carotid-femoral Pulse Wave Velocity (cfPWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence to appointment in sickle cell care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to lab draws in sickle cell care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Healthcare utilization pre and post telemedicine participation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change of Baseline Psychosocial Adaptation Questionnaire for visual impairment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Baseline Vision-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clotting time of the ROTEM assay EXTEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes